This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
There were seven screening and testing comparators and they were evaluated at intervals of one, two, and three years.
In Pap plus Pap, women aged 18 to 69 years were screened, using the Pap, and their management depended on the results of these tests. This was the strategy in use, at the time of the study, in the authors setting, with one-yearly (annual) testing.
In Pap plus HPV plus Pap, the protocol was identical to the previous one, except that women with atypical squamous cells of undetermined significance (ASCUS) were offered a HPV-DNA test for the presence of high-risk oncogenic HPV.
In Pap plus HPV plus Pap at 30 years, the protocol was identical to the first one, except that women aged 30 years or older with ASCUS were offered a HPV-DNA triage test.
In cytology plus HPV plus cytology, women aged 18 to 69 years were screened using liquid-based cytology and those with a low-grade squamous intra-epithelial lesion (LSIL) were re-tested using cytology six months later, while those with ASCUS were offered a HPV-DNA triage test, management depended on the results of the tests.
In cytology plus HPV plus cytology at 30 years, the protocol was identical to the previous one except that only women aged 30 years or older with ASCUS were offered the HPV-DNA triage test.
In HPV plus cytology plus HPV or cytology, women aged 18 to 69 years were screened, using a HPV-DNA test, and their management depended on the results of this test.
In HPV plus cytology plus HPV or cytology at 30 years, the protocol was identical to the previous one for women aged 30 years or older, while younger women received the cytology plus HPV plus cytology protocol.
Results
The expected costs and QALYs were only presented graphically.
After excluding dominated strategies, which were less effective and more costly, compared with one-year Pap plus Pap (the current pattern of care), three-year Pap plus HPV plus Pap at 30 years was dominant, while the incremental cost per QALY was CAD 58,512 with one-year Pap plus HPV plus Pap at 30 years, CAD 86,266 with one-year Pap plus HPV plus PAP, and CAD 127,076 with one-year cytology plus HPV plus cytology.
The probabilistic analysis showed that, in more than 98% of simulations, two-and three-year Pap plus Pap and one-, two-, and three-year HPV plus cytology plus HPV or cytology at 30 years were less costly and less effective than oneyear Pap plus Pap. In 63% of simulations for three-year Pap plus HPV plus Pap at 30 years and 45% for three-year cytology plus HPV plus cytology at 30 years, they were less costly and more effective than the current pattern of care.
In comparison with one-year Pap plus Pap, three-year Pap plus HPV plus Pap at 30 years was associated with a reduction in testing costs of 22.1% and physician costs of 18.6%, and an increase in in-patient costs of 0.8% and outpatient costs of 27.7%.
